---
title: "Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D… — 瑞銀 — DecisionGateway"
description: "prediction by 瑞銀, recorded recently — verbatim quote and source citation."
canonical_url: "https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d"
meta:
  "og:description": "prediction by 瑞銀, recorded recently — verbatim quote and source citation."
  "og:image": "https://dgw.tmarket.io/og.jpg"
  "og:image:alt": "White network of connected nodes crossed by a timeline on black"
  "og:image:height": "1024"
  "og:image:width": "1024"
  "og:title": "Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D… — 瑞銀 — DecisionGateway"
  "twitter:image": "https://dgw.tmarket.io/og.jpg"
---

> Index of every page on this site: [llms.txt](https://dgw.tmarket.io/llms.txt)

prediction

# **Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D competitiveness.**

A prediction by [**瑞銀**](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54). Statements are as reported by the cited publishers — not verified by DecisionGateway.

> *因此，剝離方達可能會在一定程度上影響泰格醫藥的全球佈局和跨境藥物研發競爭力。*

stockintelligencenewsPublished 2026-11-11 [ Read source](https://t.me/stockintelligencenews/5715728)

[**瑞銀 dossier **](https://dgw.tmarket.io/actors/01a1d49e-d995-7396-8810-d1e55c335b54)

## **Discussion**

## **Related claims**

[**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**Frontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3054-7ca0-a7ed-2ee97b0ffbc4) [**Tigermed announced it will participate in the privatization and business split of Frontage Holdings (01521) through its wholly-owned subsidiary Hong Kong Tigermed.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e751-3011-7670-a475-41411a6a82cf) [**Tigermed announced it will participate in the privatization and business split of Frontage Holdings through its wholly-owned subsidiary Hong Kong Tigermed.**瑞銀 · statement](https://dgw.tmarket.io/claims/01a1e74c-c273-757f-bc30-201db5377830) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**If the transaction is completed, Tigermed can also divest non-core businesses, including overseas laboratories, CMC and genomics, to focus more on clinical CRO services.**瑞銀 · prediction](https://dgw.tmarket.io/claims/01a1e74c-c2d0-77b8-a467-e3dc1b82410e)

## **More claims by 瑞銀**

[**Although divesting Frontage may affect some global synergies in the short term, the transaction can improve Tigermed's business portfolio and capital allocation while supporting further expansion of overseas clinical CRO business, supplementing working capital and raising shareholder returns.**prediction](https://dgw.tmarket.io/claims/01a1e751-3094-73c5-92e4-9c2e1b97e4fa) [**Tigermed plans to use about 60% of net cash proceeds for overseas clinical CRO expansion and M&A, 20% for daily operations, and the remaining about 20% possibly for dividends or share buybacks.**statement](https://dgw.tmarket.io/claims/01a1e751-3083-714b-9c7b-13200f21418b) [**If the transaction completes, Tigermed can divest non-core businesses including overseas laboratories, CMC and genomics to focus more on clinical CRO services.**prediction](https://dgw.tmarket.io/claims/01a1e751-306d-78f1-ac3c-2b57bdf9bbb3) [**Frontage's laboratory network in the US and Europe is an important platform linking Tigermed to global markets; it supports the strategy of dual IND filings in China and the US and helps Chinese innovative drugmakers expand overseas, so divesting Frontage may affect Tigermed's global footprint and cross-border drug R&D competitiveness to some extent.**statement](https://dgw.tmarket.io/claims/01a1e751-3054-7ca0-a7ed-2ee97b0ffbc4) [**After the privatization, Tigermed plans to acquire Frontage's mainland China non-target businesses at a preliminary valuation of about US$205.5 million; target businesses such as bioanalysis and DMPK will be sold to Charles River Laboratories at a preliminary valuation of about US$470 million; founder Li Song and related trusts may acquire the overseas non-target businesses at a preliminary valuation of about US$84.4 million.**statement](https://dgw.tmarket.io/claims/01a1e751-3034-7cb6-8adc-d678204a44df)

[All claims by 瑞銀](https://dgw.tmarket.io/claims?claimant_id=01a1d49e-d995-7396-8810-d1e55c335b54)

[All claims](https://dgw.tmarket.io/claims)

```json
{"@context":"https://schema.org","@graph":[{"@id":"https://dgw.tmarket.io/#website","@type":"WebSite","description":"Decisions, events and falsifiable forecasts — every claim cited to its public source. Read free.","name":"DecisionGateway","url":"https://dgw.tmarket.io/","publisher":{"@id":"https://dgw.tmarket.io/#identity"}},{"@id":"https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d#webpage","@type":"WebPage","description":"prediction by 瑞銀, recorded recently — verbatim quote and source citation.","name":"Divesting Frontage may to some extent affect Tigermed's global layout and cross-border drug R&D… — 瑞銀 — DecisionGateway","url":"https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d","breadcrumb":{"@id":"https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d#breadcrumb"},"isPartOf":{"@id":"https://dgw.tmarket.io/#website"},"potentialAction":[{"@type":"ReadAction","target":["https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d"]}]},{"@id":"https://dgw.tmarket.io/#identity","@type":"Organization","name":"DecisionGateway","url":"https://dgw.tmarket.io"},{"@id":"https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d#breadcrumb","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","name":"Home","item":"https://dgw.tmarket.io","position":1},{"@type":"ListItem","name":"Claims","item":"https://dgw.tmarket.io/claims","position":2},{"@type":"ListItem","name":"Divesting Frontage may to some extent affect Tigermed's…","position":3}]},{"@id":"https://dgw.tmarket.io/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d#/schema/quotation/1","@type":"Quotation","dateCreated":"2026-11-11","isBasedOn":"https://t.me/stockintelligencenews/5715728","text":"因此，剝離方達可能會在一定程度上影響泰格醫藥的全球佈局和跨境藥物研發競爭力。","url":"/claims/01a1e74c-c2c2-7c6f-8bee-907f32b5c44d","spokenByCharacter":{"@type":"Person","name":"瑞銀","@id":"/actors/01a1d49e-d995-7396-8810-d1e55c335b54"}}]}
```

## Sitemap

See the full [sitemap](https://dgw.tmarket.io/sitemap.md) for all pages.
